Pharmacokinetic interactions between arbaprostil and aspirin in humans

Arbaprostil is an orally active prostaglandin E2 analogue. It has been developed as a drug to treat ulcers induced by non-steroidal anti-inflammatory drugs. In this study, pharmacokinetic interactions between arbaprostil and aspirin were examined in humans after chronic doses of both drugs. Subjects received either arbaprostil (50 μg), asprin (975 mg) or arbaprostil (50 μg) and aspirin (975 mg) four times a day for 6 days and one dose on 7th day. Blood and urine samples were collected after the last dose for 6 h. Pharmacokinetic parameters of arbaprostil, aspirin, and Salicylate were determined. Coadministration of arbaprostil significantly lowered the area under curve (5·09 ± 0·32 μg hml−1vs 5·78 ± 0·29 μg hml−1, mean ± SE, p < 0·05) and time (0·45 ± 0·07 h vs 0·70 ± 0·12 h, p < 0·05) to reach maximal plasma concentration of aspirin (acetylsalicylate). The pharmacokinetics of salicylate were not changed by arbaprostil, nor were the pharmacokinetics of arbaprostil affected by aspirin. Coadministration of these two drugs did not appear to potentiate the side-effects of either drug. The results suggest that arbaprostil and aspirin may be administered together without clinically significant changes in pharmacokinetics or adverse side-effects.